Mission Pharmacal Header

Mission Pharmacal Header

X

Find Gastroenterology Drugs in Phase II Clinical Development in ISRAEL

Filters

×

FILTER:

filter

News Type

filter

Company

filter

Product Type

filter

Deal Size

filter

Upfront Payment

Active Filter(s):

Filters

Reset Filter

All Developments

Product Type

Companies

[{"company":"RedHill Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"RedHill Biopharma Regains Rights to its Proprietary Bowel Preparation RHB-106","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"ISRAEL","productType":"Small molecule","productStatus":"Approved","date":"January 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"RedHill Biopharma"}]

RedHill Biopharma

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

RedHill Biopharma Regains Rights to its Proprietary Bowel Preparation RHB-106

Details:

RedHill Biopharma Regains Rights to its Proprietary Bowel Preparation RHB-106 & announced that it has provided Salix Pharmaceuticals Ltd. (Salix) with a notice of termination of their 2014 license agreement.

Lead Product(s): RHB-106

Therapeutic Area: Gastroenterology Product Name: Undisclosed

Highest Development Status: Phase II Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 02, 2020

ASK
US

Upload
your Pipeline Activity

POST ENQUIRY